子衍生的酸YYLLVR通过激活ACE2来改善高血压中的内皮功能障碍
Wentian Song1,2,3, Haoduo Huang1,2,3, Yue Shen3
1National Key Laboratory for Development and Utilization of Forest Food Resources, Zhejiang A&F University, Hangzhou, Zhejiang 311300, China.
Journal of agricultural and food chemistry
|June 16, 2025
概括
桃YYLLVR有效降低血压,并改善高血压大鼠的内皮功能. 这种新型的ACE2激活显示出治疗高血压和相关血管功能障碍的治疗潜力.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压和内皮功能障碍是显著的心血管风险因素.
- 氨酸-血管氨系统 (RAS) 在血压调节中起着至关重要的作用.
- 准ACE2/Ang-(1-7) /MAS轴为高血压提供了一个潜在的治疗策略.
研究的目的:
- 为了研究YYLLVR的抗高血压作用,YYLLVR是一种子衍生的.
- 确定YYLLVR对自发高血压大鼠 (SHRs) 内皮功能障碍的影响.
- 阐明YYLLVR作用背后的分子机制,重点关注ACE/Ang II/AGTR1和ACE2/Ang-{1-7) /MAS通路.
主要方法:
- 对自发高血压大鼠 (SHRs) 给予YYLLVR.
- 测量心压和心压血压.
- 在体外 (HUVEC) 和体内 (in vivo) 评估ACE2表达和活性.
- 对关键分子标记物的分析,包括氧化 (NO),ENOS,ET-1,iNOS和炎症性细胞因子 (IL-1β).
- 评估内皮细胞亡,管形成,迁移和增殖.
主要成果:
- 在SHR中,YYLLVR显著降低了静缩 (53.48 mmHg) 和静缩 (37.57 mmHg) 血压.
- YYLLVR增加了ACE2表达 (2倍) 和活性,促进了ACE2/Ang-(1-7) /MAS轴,同时抑制了ACE/Ang II/AGTR1轴.
- 观察到增强的NO和eNOS表达,减少ET-1和eNOS表达,以及降低大动脉厚度.
- YYLLVR证明了对Ang II诱导的亡的保护作用,并改善了内皮细胞功能.
- YYLLVR的效果取决于ACE2活性,这是用ACE2抑制剂 (DX600) 进行的实验证实的.
结论:
- YYLLVR具有强大的抗高血压作用,并改善内皮功能障碍.
- 它的机制涉及ACE2/Ang-(1-7) /MAS途径的激活和血管炎症和重塑的调节.
- YYLLVR代表了一种有前途的新型ACE2激活,用于治疗高血压和内皮功能障碍.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
913
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
913
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
950
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
950
01:29Hypertension II: Pathophysiology
91
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
91
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
01:25Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849